# The mitochondrial tRNA<sup>Ala</sup> 5587T>C and tRNA<sup>Leu(CUN)</sup> 12280A>G mutations may be associated with hypertension in a Chinese family

LIN LIN $^1,\,$  PENG CUI $^2,\,$  ZHIPENG QIU $^3,\,$  MIN WANG $^3,\,$  YINGCHAO YU $^3,\,$  JING WANG $^4,\,$  QIAN SUN $^4\,$  and HAIRONG ZHAO $^5\,$ 

<sup>1</sup>Health Examination Department; <sup>2</sup>Multidisciplinary Consultation Center; <sup>3</sup>Emergency Department;

<sup>4</sup>Department of Joint Surgery; <sup>5</sup>Department of General Medicine, Affiliated Qingdao Hiser Hospital of Qingdao University,

Qingdao, Shandong 266000, P.R. China

Received June 3, 2018; Accepted December 6, 2018

DOI: 10.3892/etm.2018.7143

Abstract. Hypertension is a very common cardiovascular disorder, however, the molecular mechanism underlying this disease remains poorly understood. Recently, an increasing number of studies have demonstrated that mitochondrial (mt)DNA mutations serve important roles in the pathogenesis of hypertension. The current study reported the clinical and molecular characterization of a Chinese family with maternally inherited hypertension (the penetrance of hypertension was 71.4%). In addition, the entire mitochondrial transfer (mt-t)RNA genomes was amplified using a polymerase chain reaction (PCR) and identified through direct Sanger sequencing. Additionally, the mtDNA copy number in matrilineal relatives in this family was evaluated using quantitative PCR. The sequence analysis of the 22 mt-tRNA genes led to the identification of tRNA<sup>Ala</sup> 5587T>C (thymine to cytosine) and tRNA<sup>Leu(CUN)</sup> 12280A>G (adenine to guanine) mutations. Notably, the heteroplasmic 5587T>C mutation was located at the 3' end of tRNA<sup>Ala</sup> (position 73), which is highly conserved from bacteria to human mitochondria. In addition, the 12280A>G mutation was revealed to occurs at the dihydrouridine loop of tRNA<sup>Leu(CUN)</sup> (position 15) and may decrease the steady-state level of mt-tRNA. As a result, 5587T>C and 12280A>G mutations may lead to the failure of tRNAs metabolism and subsequently cause mitochondrial protein synthesis defects. Molecular analysis revealed that patients carrying the 5587T>C and 12280A>G mutations had a lower copy number of mtDNA compared with a control with hypertension, but without the mutations, suggesting that these mutations may cause mitochondrial dysfunctions that are responsible for hypertension. Therefore, mt-tRNA<sup>Ala</sup> 5587T>C and tRNA<sup>Leu(CUN)</sup> 12280A>G mutations may be involved in the pathogenesis of hypertension in this family.

## Introduction

Hypertension is a major public health problem, affecting approximately 1 billion people worldwide (1). Hypertension is also an established risk factor for coronary heart disease, stroke and renal failure (2). Despite significant advances in the understanding of the pathophysiology of hypertension, it remains to be one of the most challenging disorders (3). It is generally believed that hypertension is influenced by genetic and environmental factors. Estimates of genetic variance range from 20-50% (4), and maternal and paternal patterns have been reported (5). In fact, previous studies demonstrated that mitochondrial dysfunction caused by mitochondrial (mt)DNA mutations were important causes for hypertension (6). Several mitochondrial transfer (mt-t)RNA mutations have been reported to be associated with hypertension, these mutations include mt-tRNA<sup>Ala</sup> 5587T>C (thymine to cytosine) (7); mt-tRNA<sup>Gln</sup> 4375C>T (8), mt-tRNA<sup>Met</sup> 4435A>G (9) and mt-tRNA<sup>Leu(CUN)</sup> 12280A>G (adenine to guanine) (10). The authors of the current study noticed that these mutations may decrease the steady-state level of mt-tRNAs and subsequently cause the mitochondrial dysfunction that is responsible for hypertension. Nevertheless, the association between mtDNA mutations and high blood pressure remains unclear.

To investigate the contribution of mtDNA mutations to hypertension, a mutational analysis for mt-tRNA genes was performed in a large cohort of patients with hypertension. In the current study, the authors described a Han Chinese family with maternally transmitted hypertension. Sequence analysis of the 22 mt-tRNA genes led to the identification of two potential pathogenic mutations: tRNA<sup>Ala</sup> 5587T>C and tRNA<sup>Leu(CUN)</sup> 12280A>G. The mtDNA copy number in the patients carrying these mutations was then analysed.

*Correspondence to:* Professor Hairong Zhao, Department of General Medicine, Affiliated Qingdao Hiser Hospital of Qingdao University, 4 Renming Road, Qingdao, Shandong 266000, P.R. China E-mail: zhaohairongqd@sina.com

*Key words:* hypertension, mitochondrial, tRNA, mutations, 5587T>C, 12280A>G

## **Patients and methods**

Pedigree information. A Han Chinese family (Fig. 1) with maternally inherited hypertension was recruited to the current study from department of General Medicine, Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao, China). There were 13 individuals in this family; five matrilineal relatives (I-2, II-4, II-6, III-5 and III-6) and an unrelated member of the family (II-5) suffered from hypertension, although II-5 did not have the investigated mutations (Fig. 1). Notably, members including I-2 (proband's mother), II-4 (proband), II-5 (proband's brother-in-law), II-6 (proband's sister), III-5 (proband's daughter) and III-6 (proband's niece) were involved in the current study. This protocol was approved by the ethics committee of the Affiliated Qingdao Hiser Hospital of Qingdao University. Detailed demographics, anthropometrics, vital parameters and medical history were recorded for each individual during interviews. Additionally, 500 unrelated Han Chinese healthy subjects (200 males and 300 females; age range, 21-55 years; mean age, 40±1.5 years) were collected from the Health Examination Department, Affiliated Qingdao Hiser Hospital of Qingdao University and used as controls; written informed consent was obtained from all subjects involved in the current study. Notably, the control subjects were healthy individuals, without any diseases or any family history of mitochondrial disorders, including deafness, vision loss, neurological disorders or cardiovascular diseases. Control subjects who had a family history of mitochondrial diseases were excluded.

Measurement of the blood pressure (BP). Members of this family, as well as 500 healthy subjects underwent BP assessments; two doctors measured the systolic and diastolic BP via an electronic measuring device, and repeated three times. Hypertension was defined according to the guidelines of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI) (11) and the World Health Organization-International Society of Hypertension (12) as a systolic BP of  $\geq$ 140 mmHg and/or a diastolic BP of  $\geq$ 90 mmHg, or a history of hypertension with current antihypertensive drug treatment (13).

Detecting the hypertension-associated mt-tRNA mutations. The blood samples of each individual were collected in sterile ethylenediaminetetraacetic acid test tubes. To analysis the mutations/polymorphisms in mt-tRNA genes, the genomic DNA was extracted from the blood samples using the Puregene DNA Isolation kit (Gentra Systems, Inc., Minneapolis, MN, USA). The 22 mt-tRNA genes were polymerase chain reaction (PCR) amplified using 11 primers as described previously (7). The PCR products were purified and analyzed by direct sequencing in an ABI 3700 automated DNA sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) using a Big Dye Terminator Cycle sequencing reaction kit version 3.1 (Applied Biosystems; Thermo Fisher Scientific, Inc.). DNA Star software version 5.01 (DNASTAR Inc., Madison, WI, USA) was used to identify genetic variants in mt-tRNAs by comparing the sequence data with the Cambridge reference sequence (NC\_012920) (14) and the protocols of Sanger sequencing; the Sanger sequencing primers were described in a previous investigation (15).

*mt-tRNA structure analysis*. The published secondary structures of mt-tRNA<sup>Leu(CUN)</sup> and tRNA<sup>Ala</sup> were used to define the stem-and-loop structure (16). Using the cloverleaf structure, the position of the 12280A>G and 5587T>C mutations were localized.

Analysis of the conservation index (CI). To assess the potential pathogenic roles of the tRNA<sup>Leu(CUN)</sup> 12280A>G and tRNA<sup>Ala</sup> 5587T>C mutations, the CIs of the mutations were evaluated using phylogenetic conservation analysis (7). The following species were selected for the phylogenetic conservation analysis: Homo sapiens, Gorilla gorilla, Macaca mulatta, Pan paniscus, Papio hamadryas, Trachypithecus obscures, Muntiacus reevesi, Mus musculus, Balaenoptera bonaerensis, Cynocephalus variegates and Pongo pygmaeus abelii. The CI was calculated by comparing the human mtDNA variants with other species; a CI>75% was considered to have functional potential (17).

Analysis of mtDNA content. To see whether tRNA<sup>Leu(CUN)</sup> 12280A>G and tRNA<sup>Ala</sup> 5587T>C mutations caused mitochondrial dysfunction, the mtDNA content from each individual with hypertension was determined using quantitative PCR and the  $2^{-\Delta\Delta Cq}$  method (18). The mtDNA content was normalized to a single copy nuclear gene ( $\beta$ -globin). The primer sequences for amplifying the gene were as follows: mtDNA ND1: Forward, 5'-AACATACCCATGGCCAAC CT-3' and reversed, 5'-AGCGAAGGGTTGTAGTAGCCC-3'; and β-globin: Forward, 5'-GAAGAGCCAAGGACAGGT AC-3' and reverse, 5'-CAACTTCATCCACGTTCACC-3. The PCR reaction solution (20  $\mu$ l) contained 2X Taqman Universal PCR Master Mix (Takara Biotechnology Co., Ltd., Dalian, China), 500 nmol/l of each primer, 200 nmol/l Taqman Probe and 100 ng of total DNA. The PCR conditions were as follows: 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of denaturation for 15 sec at 95°C and 60 sec annealing/extension at 60°C. Each experiment was repeated three times.

*Statistical analysis.* The statistical analysis was performed using the SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Differences in categorical variables were assessed with Fisher's exact test. P<0.05 indicated that the difference between groups was statistically significant.

### Results

*Clinical analysis.* A maternally transmitted Han Chinese family with hypertension (Fig. 1) was recruited from the Affiliated Qingdao Hiser Hospital of Qingdao University. The proband (II-4) was a 55-year-old female who was admitted to the department of General Medicine, Affiliated Qingdao Hiser Hospital of Qingdao University with a high BP (140/95 mmHg). The proband did not smoke or drink alcohol and did not have a history of coronary heart disease, renal failure or hyperlipidemia. In addition, the authors of the current study observed that the age of onset from the first generation was 66 years, while



Figure 1. One Han Chinese family with hypertension carrying the mt-tRNA<sup>Ala</sup>5587T>C and tRNA<sup>Leu(CUN)</sup> 12280A>G mutations. The affected individuals are presented as filled symbols, the arrow indicates the proband. mt, mitochondrial; t, transfer.

the mean age of onset were younger for the second generation (43.5 years, ranged between 42 and 45 years) and the third generation (32.0 years, ranged between 30 and 34 years); the mean age of onset of hypertension for the affected members of the family was  $43.50 \pm 12.52$  years. The BP of each individual with hypertension was listed in Table I.

Mutational screening for mt-tRNA genes and structural analysis. The hypertension was maternally transmitted, which suggested that mitochondrial dysfunction may be the molecular basis for this disease; in addition, recent experimental studies suggested a positive association between mt-tRNA mutations and hypertension (19,20). Therefore, the mt-tRNA mutations were analyzed from the matrilineal relatives (I-2, II-1, II-4, II-6, III-4, III-5 and III-6) from this pedigree. The PCR was performed to amplify the entire mt-tRNAs, the PCR products were then purified and analyzed by direct sequencing. As a result, two mutations were identified: A homoplasmic tRNA<sup>Leu(CUN)</sup> 12280A>G mutation and a heteroplasmic tRNA<sup>Ala</sup> 5587T>C mutation in the matrilineal relatives (I-2, II-1, II-4, II-6, III-4, III-5 and III-6) with hypertension (Fig. 2), and no other mt-tRNA mutations were identified in the family. The 12280A>G mutation was localized at position 15 in the dihydrouridine (DHU)-loop of tRNA<sup>Leu(CUN)</sup> (Fig. 3), which was highly conserved from various species (Table II). Notably, the 12280A>G created a novel base-pairing (15C-19G) and may cause the failure in tRNA metabolism. While the 5587T>C mutation occurred at position 73 near the end of tRNA<sup>Ala</sup>; notably, the T to C transition at position 73 was extremely conserved, suggesting that the 5587T>C mutation may alter the secondary structure of tRNA<sup>Ala</sup> (21). The 5587T>C and 12280A>G mutations was not identified in 500 healthy subjects; the Fisher's exact test was performed and it was revealed that the 5587T>C and 12280A>G had statistical significance (both P<0.05; Table III).

*Evolutionary conservation assessment*. To evaluate potential pathogenic mutations, evolutionary conservation was assessed. The CIs of 12280A>G and 5587T>C mutations were analyzed, demonstrating them as 100% (Table II); a recent report by

Ji *et al* (21) also revealed that the CI of the 5587T>C mutation was 100%.

*mtDNA copy number analysis*. As shown in Fig. 4, patients carrying mt-tRNA<sup>Leu(CUN)</sup> 12280A>G and tRNA<sup>Ala</sup> 5587T>C mutations have markedly a lower copy number of mtDNA compared with a control with hypertension, but without the mutations, suggesting that the 12280A>G and/or 5587T>C mutation may cause mitochondrial dysfunction by altering the mtDNA content.

#### Discussion

The present study reported that the clinical and molecular characterization of a Chinese pedigree with maternally inherited hypertension. Although many studies revealed the genetics of mitochondrial disorders, the molecular mechanism underlying hypertension remains unclear (22,23). Experimental studies identified a positive association between mtDNA mutations and hypertension (24,25). In particular, Watson et al (26) reported a double ND3 10398A>G Ddel CO1 HaeIII 6620T>C or 6260G>A mutation in hypertensive African-Americans with end-stage renal disease. In addition, in a recent case-control study, Liu et al (27) identified several mt-tRNA mutations that were associated with hypertension, including tRNA<sup>Phe</sup> 586G>A, tRNA<sup>Lys</sup> 8313G>A and tRNA<sup>His</sup> 12147G>A, suggesting that mt-tRNA genes were likely to contain pathogenic mutations associated with hypertension.

For this purpose, the mutations/variants in 22 mt-tRNA genes from the matrilineal relatives in the pedigree were screened and two potential pathogenic mutations identified were: mt-tRNA<sup>Ala</sup> 5587T>C and tRNA<sup>Leu(CUN)</sup> 12280A>G. It was interesting to note that the heteroplasmic 5587T>C mutation occurred at the 3' end of tRNA<sup>Ala</sup>, which is very important for tRNA identity (28). Additionally, this mutation has been reported to be associated with Leber's hereditary optic neuropathy (21), hearing loss, progressive unstable gait, dysarthria, muscle cramps and myalgias (29). Functional analysis indicated that the 5587T>C mutation affected the aminoacylation

Subjects	Sex	Age of onset (years)	Systolic pressure (mmHg)	Diastolic pressure (mmHg)
I-2	F	66	155	90
II-4	F	45	140	95
II-6	F	42	145	85
III-5	F	34	145	90
III-6	F	30	150	75
II-5	М	n/a	130	75

Table I. Clinical information for family members with hypertension.

F, female; M, male; n/a, not applicable.



Figure 2. Identification of 5587T>C and 12280A>G mutations using direct sequencing.



Figure 3. Structure of tRNA and location of the mutations. (A) The 5587T>C mutation is localized at the 3' end of tRNA<sup>Ala</sup>. (B) The 12280A>G mutation occurs at DHU loop of tRNA<sup>Leu(CUN)</sup>. DHU, dihydrouridine.

of tRNA<sup>Ala</sup> and efficiency of mitochondrial translation (21). Thus, the 5587T>C mutation may have the same impact for the pathogenesis of hypertension in this family.

Furthermore, the homoplasmic 12280A>G mutation was found at position 15 in the DHU loop of the tRNA<sup>Leu(CUN)</sup> gene, which was extremely conserved in various species. Notably, the

om different species.
frc
gene
$t-tRNA^{Leu(CUN)}$
Ξ
f the
õ
Alignment
Π.
Table

Organism	Acc-stem	D-stem	D-loop	D-stem	Ac-Stem	Anticd- loop	Ac-stem	V-region	T-stem	T-loop	T-stem	Acc-stem
Homo sapiens	ACTTTT AAA	GGAT	AACA GCT	ATCCA	TTGGT	CTTA GGC	CCCAA	AAAT	TTTGG	TGCA ACT	CCAAA	TAAAA GTA
Gorilla gorilla	ACTTTT AAA	GGAT	AACA GCT	ATCCA	TJGGT	CTTA GGA	CCCAA	AAAT	TTTGG	TGCA	CCAAA	TAAAA GTA
Macaca mulatta	ACTTTT AAA	GGAT	AACA	ATCCA	TTGAC	CTTA	GTCAA	AAAC	ATTGG	TGCA	CCAAA	TAAAA GTA
Pan paniscus	ACTTTT AAA	GGAT	AACA	ATCCG	TTGGT	CTTA	CCCAA	AAAT	TTTGG	TGCA	CCAAA	TAAAA GTA
Papio	ACTTTT	GGAT	AACA	ATCCA	TTGGT	CTTA	ACCAA	AAAC	ATTGG	TGCA	CCAAA	TAAAA
rumuar yas Trachypithecus	ACTTTT	GGAT	AACA	ATCCG	TTGGT	CTTA	ACCAA	AAAT	ATTGG	TGCA	CCAAA	TAAAA
obscurus Muntiacus reevesi	AAA ACTTTT ACA	GGAT	GACA CAT	ATCCG	TTGGT	GGA CTTA	ATCAA	AAA	ATTGG	TGCA	CCAAA	GIA TAAAA CTA
Mus musculus	AUA ACTTTT ATA	GGAT	GAI AATA GTA	ATCCA	TJGGT	CTTA CTTA GGA	ACCAA	AAAC	CTTGG	ACI TGCA AAT	CCAAA	UIA TAAAA GTA
Balaenoptera bonaerensis	ACTTTT ACA	GGAT	AACA GTT	ATCCA	TJGGT	CTTA GGA	ACCAA	AAA	ATTGG	TGCA	CCAAA	TAAAA GTA
Cynocephalus variegatus	ACTTTC AAA	GGAT	AAAA GCA	ATCCA	TJGGT	CTTA GGA	ACCAA	AAAA	TTTGG	TGCA ACT	CCAAA	TGAAA GTA
Pongo pygmaeus abelii	ACTTTT AAA	GGAT	AACA GCT	ATCCC	TTGGT	CTTA GGA	CCCAA	AAAT	TTTGG	TGCA ACT	CCAAA	TAAAA GTA
The red letter indicates	position 15, which	ch corresponds	to the 12280A	N>G mutation.								

			Number of with the two	individuals o mutations	
Genes	Position	Replacement	Patients (%)	Controls (%)	P-value
tRNA <sup>Ala</sup>	5,587	T to C	5 (100)	0	< 0.05
$tRNA^{Leu(CUN)}$	12,280	A to G	5 (100)	0	< 0.05

Table III. 5587T>	>C and 12280A	>G mutations	identified in	n affected i	individuals,	but not controls
-------------------	---------------	--------------	---------------	--------------	--------------	------------------

A total of 500 healthy tissues were used as controls.



Figure 4. Quantification of mtDNA copy number. mt, mitochondrial.

12280A>G mutation created a novel base-pairing (15G-19C), which may alter its tertiary structure. Importantly, nucleotides at the same positions in mt-tRNA<sup>IIe</sup> gene (4277T>C mutation) has been reported to be associated with hypertrophic cardio-myopathy (30). Therefore, the authors of the current study propose that the 12280A>G mutation may have the same impact on hypertension.

To see whether 5587T>C and 12280A>G mutations caused the mitochondrial dysfunction, the mtDNA copy number in patients carrying these mutations were evaluated using quantitative PCR. Consequently, it was determined that patients with these mutations have a lower copy number of mtDNA compared with a control with hypertension, but without the mutations, which is consistent with a previous study (31). In fact, the alteration of the mtDNA copy number, which reflects oxidant-induced cell damage, had been observed in a wide range of human mitochondrial diseases (32). Additionally, a decreased mtDNA copy number has been demonstrated to lead to increased ROS levels; ROS induced by mitochondrial dysfunction can increase mitochondrial Ca<sup>2+</sup> accumulation and may act as potential pathophysiological mechanism in hypertension (33,34).

In conclusion, the authors of the current study hypothesise that mt-tRNA<sup>Ala</sup> 5587T>C and tRNA<sup>Leu(CUN)</sup> 12280A>G mutations possibly lead to molecular mechanisms that underlie the progression of maternally inherited essential hypertension. The molecular mechanisms may be as follows: The mutations altered the secondary structure of tRNA<sup>Ala</sup> and tRNA<sup>Leu(CUN)</sup>, subsequently, the structural alternations led to a decrease in the steady-state levels of tRNA<sup>Ala</sup> and tRNA<sup>Leu(CUN)</sup>, and caused the impairments of mt-tRNAs metabolism. As a result, mitochondrial protein synthesis, the respiration chain and ATP levels declined significantly; additionally, decreased tRNA steady-state levels may also affect tRNA aminoacylation, mtDNA copy number and ROS generation (35,36). Therefore, the mitochondrial dysfunction, caused by 5587T>C and 12280A>G mutations, may contribute to the progression of hypertension in this family. In fact, mutations that caused the mt-tRNA metabolism failure suggest a possible metabolic pathway, as indicated in several studies (37-39). However, the incomplete penetrance of hypertension and variable degree of blood pressure indicated that the 5587T>C and 12280A>G mutations were insufficient to produce the clinical phenotypes; thus, other modifiable factors, including environmental factors, nuclear genes and epigenetic modification may account for hypertension expression. The tRNA<sup>Ala</sup> 5587T>C and tRNA<sup>Leu(CUN)</sup> 12280A>G mutations should be added as risk factors for familial hypertension. The main limitation of the current study was the lack of functional experiments. Thus further investigations using trans-mitochondrial cybrid cells should be employed to determine the mitochondrial dysfunctions caused by 5587T>C and 12280A>G mutations, including assessing ROS production, ATP production and mitochondrial membrane potential.

# Acknowledgements

Not applicable.

#### Funding

No funding was received.

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

# Authors' contributions

LL and HZ designed the current study. LL, PC, ZQ, MW, YY, JW and QS performed clinical and molecular analyses. HZ wrote the manuscript. All authors approved the final manuscript.

#### Ethics approval and consent to participate

The protocol of the current study was approved by the ethics committee of the Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao, China). Written informed consent was obtained from all subjects involved in the current study.

#### Patient consent for publication

All patients agreed for the publication of their data.

#### **Competing interests**

The authors declare that they have no competing interests.

#### References

- Guidelines Subcommittee. World health organization-international society of hypertension guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 17: 151-183, 1999.
- Kannel WB: Risk stratification in hypertension: New insights from the Framingham Study. Am J Hypertens 13: S3-S10, 2000.
   El Shamieh S, Herbeth B, Azimi-Nezhad M, Benachour H,
- El Shamieh S, Herbeth B, Azimi-Nezhad M, Benachour H, Masson C and Visvikis-Siest S: Human formyl peptide receptor 1 C32T SNP interacts with age and is associated with blood pressure levels. Clin Chim Acta 413: 34-38, 2012.
- 4. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, *et al*: High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38: 515-517, 2006.
- Choi SJ, Lee HK, Kim NH and Chung SY: Mycophenolic acid mediated mitochondrial membrane potential transition change lead to T lymphocyte apoptosis. J Korean Surg Soc 81: 235-241, 2011.
- Ding Y, Xia B, Yu J, Leng J and Huang J: Mitochondrial DNA mutations and essential hypertension (Review). Int J Mol Med 32:768-774, 2013.
- Zheng P, Li S, Liu C, Zha Z, Wei X and Yuan Y: Mitochondrial tRNAAla C5601T mutation may modulate the clinical expression of tRNA<sup>Met</sup> A4435G mutation in a Han Chinese family with hypertension. Clin Exp Hypertens 40: 595-600, 2018.
- hypertension. Clin Exp Hypertens 40: 595-600, 2018.
  8. Chen H, Sun M, Fan Z, Tong M, Chen G, Li D, Ye J, Yang Y, Zhu Y and Zhu J: Mitochondrial C4375T mutation might be a molecular risk factor in a maternal Chinese hypertensive family under haplotype C. Clin Exp Hypertens 40: 518-523, 2018.
- Lu Z, Chen H, Meng Y, Wang Y, Xue L, Zhi S, Qiu Q, Yang L, Mo JQ and Guan MX: The tRNAMet 4435A>G mutation in the mitochondrial haplogroup G2a1 is responsible for maternally inherited hypertension in a Chinese pedigree. Eur J Hum Genet 19: 1181-1186, 2011.
   Teng L, Zheng J, Leng J and Ding Y: Clinical and molecular
- Teng L, Zheng J, Leng J and Ding Y: Clinical and molecular characterization of a Han Chinese family with high penetrance of essential hypertension. Mitochondrial DNA 23: 461-465, 2012.
- Jones D, Basile J, Cushman W, Egan B, Ferrario C, Hill M, Lackland D, Mensah G, Moore M, Ofili E, *et al*: Managing hypertension in the southeastern United States: Applying the guidelines from the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Am J Med Sci 318: 357-364, 1999.
   Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L,
- 12. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, Neal B, Rodgers A, Ni Mhurchu C and Clark T: 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 21: 1009-1060, 1999.
- 13. Muntner P, Krousel-Wood M, Hyre AD, Stanley E, Cushman WC, Cutler JA, Piller LB, Goforth GA and Whelton PK: Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines. Hypertension 53: 617-623, 2009.

- 14. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM and Howell N: Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet 23: 147, 1999.
- Rieder MJ, Taylor SL, Tobe VO and Nickerson DA: Automating the identification of DNA variations using quality-based fluorescence re-sequencing: Analysis of the human mitochondrial genome. Nucleic Acids Res 26: 967-973, 1998.
- Šuzuki T, Nagao A and Suzuki T: Human mitochondrial tRNAs: Biogenesis, function, structural aspects, and diseases. Annu Rev Genet 45: 299-329, 2011.
- Levin L, Zhidkov I, Gurman Y, Hawlena H and Mishmar D: Functional recurrent mutations in the human mitochondrial phylogeny: Dual roles in evolution and disease. Genome Biol Evol 5: 876-890, 2013.
- Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ and Reed MW: Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: Comparison of endpoint and real-time methods. Anal Biochem 285: 194-204, 2000.
- 19. Xu Y, Chen X, Huang H and Liu W: The mitochondrial tRNA<sup>Ala</sup> T5655C mutation may modulate the phenotypic expression of tRNA<sup>Met</sup> and tRNA<sup>Gln</sup> A4401G mutation in a Han Chinese family with essential hypertension. Int Heart J 58: 95-99, 2017.
- 20. Guo L, Yuan Y and Bi R: Mitochondrial DNA mutation m.5512A >G in the acceptor-stem of mitochondrial tRNA<sup>Trp</sup> causing maternally inherited essential hypertension. Biochem Biophys Res Commun 479: 800-807, 2016.
- 21. Ji Y, Qiao L, Liang X, Zhu L, Gao Y, Zhang J, Jia Z, Wei QP, Liu X, Jiang P and Guan MX: Leber's hereditary optic neuropathy is potentially associated with a novel m.5587T>C mutation in two pedigrees. Mol Med Rep 16: 8997-9004, 2017.
- 22. Tranchant Č and Anheim M: Movement disorders in mitochondrial diseases. Rev Neurol (Paris) 172: 524-529, 2016.
- 23. Ma K, Xie M, He X, Liu G, Lu X, Peng Q, Zhong B and Li N: A novel compound heterozygous mutation in VARS2 in a newborn with mitochondrial cardiomyopathy: A case report of a Chinese family. BMC Med Genet 19: 202, 2018.
- Zhu Ý, Gu X and Xu C: Mitochondrial DNA 7908-8816 region mutations in maternally inherited essential hypertensive subjects in China. BMC Med Genomics 11: 89, 2018.
   Zhao Y, Chen X, Li H, Zhu C, Li Y and Liu Y: Mitochondrial
- 25. Zhao Y, Chen X, Li H, Zhu C, Li Y and Liu Y: Mitochondrial genome mutations in 13 subunits of respiratory chain complexes in Chinese Han and Mongolian hypertensive individuals. Mitochondrial DNA A DNA Mapp Seq Anal 29: 1090-1099, 2018.
- 26. Watson B Jr, Khan MA, Desmond RA and Bergman S: Mitochondrial DNA mutations in black Americans with hypertension-associated end-stage renal disease. Am J Kidney Dis 38, 529-536, 2001.
- Liu Y, Li Y, Wang X, Ma Q, Zhu C, Li Z, Yin T, Yang J, Chen Y and Guan M: Mitochondrial tRNA mutations in Chinese hypertensive individuals. Mitochondrion 28: 1-7, 2016.
- Levinger L, Mörl M and Florentz C: Mitochondrial tRNA 3' end metabolism and human disease. Nucleic Acids Res 32: 5430-5431, 2004.
- 29. Crimi M, Sciacco M, Galbiati S, Bordoni A, Malferrari G, Del Bo R, Biunno I, Bresolin N and Comi GP: A collection of 33 novel human mtDNA homoplasmic variants. Hum Mutat 20: 409, 2002.
- 30. Perli E, Giordano C, Tuppen HA, Montopoli M, Montanari A, Orlandi M, Pisano A, Catanzaro D, Caparrotta L, Musumeci B, *et al*: Isoleucyl-tRNA synthetase levels modulate the penetrance of a homoplasmic m.4277T>C mitochondrial tRNA(Ile) mutation causing hypertrophic cardiomyopathy. Hum Mol Genet 21: 85-100, 2012.
- 31. Lei L, Guo J, Shi X, Zhang G, Kang H, Sun C, Huang J and Wang T: Mitochondrial DNA copy number in peripheral blood cell and hypertension risk among mining workers: A case-control study in Chinese coal miners. J Hum Hypertens 31: 585-590, 2017.
- study in Chinese coal miners. J Hum Hypertens 31: 585-590, 2017.
  32. Huang J, Tan L, Shen R, Zhang L, Zuo H and Wang DW: Decreased peripheral mitochondrial DNA copy number is associated with the risk of heart failure and long-term outcomes. Medicine (Baltimore) 95: e3323, 2016.
- 33. Ding Y, Xia BH, Zhang CJ and Zhuo GC: Mitochondrial tRNA<sup>Leu(UUR)</sup> C3275T, tRNA<sup>GIn</sup> T4363C and tRNA<sup>Lys</sup> A8343G mutations may be associated with PCOS and metabolic syndrome. Gene 642: 299-306, 2018.
- 34. Schaar CE, Dues DJ, Spielbauer KK, Machiela E, Cooper JF, Senchuk M, Hekimi S and Van Raamsdonk JM: Mitochondrial and cytoplasmic ROS have opposing effects on lifespan. PLoS Genet 11: e1004972, 2015.

- 35. Asano K, Suzuki T, Saito A, Wei FY, Ikeuchi Y, Numata T, Tanaka R, Yamane Y, Yamamoto T, Goto T, *et al*: Metabolic and chemical regulation of tRNA modification associated with taurine deficiency and human disease. Nucleic Acids Res 46: 1565-1583, 2018.
- Salinas-Giegé T, Giegé R and Giegé P: tRNA biology in mitochondria. Int J Mol Sci 16: 4518-4559, 2015.
- 37. Zhou M, Xue L, Chen Y, Li H, He Q, Wang B, Meng F, Wang M and Guan MX: A hypertension-associated mitochondrial DNA mutation introduces an m1G37 modification into tRNA<sup>Met</sup>, altering its structure and function. J Biol Chem 293: 1425-1438, 2018.
- Li H, Geng J, Yu H, Tang X, Yang X and Xue L: Mitochondrial tRNAThr 15909A>G mutation associated with hypertension in a Chinese Han pedigree. Biochem Biophys Res Commun 495: 574-581, 2018.
   Zhou M, Wang M, Xue L, Lin Z, He Q, Shi W, Chen Y, Jin X, Li H,
- 39. Zhou M, Wang M, Xue L, Lin Z, He Q, Shi W, Chen Y, Jin X, Li H, Jiang P and Guan MX: A hypertension-associated mitochondrial DNA mutation alters the tertiary interaction and function of tRNALeu(UUR). J Biol Chem 292: 13934-13946, 2017.